title: The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma.
abstract: BACKGROUND
  Recent reports have shown that deleted in breast cancer 1 (DBC1/CCAR2) is an indicator of poor prognosis of various human cancers. However, its expression in ovarian carcinoma has not been reported.
  
  
  METHODS
  We investigated the immunohistochemical expression of DBC1 and BRCA1 and their prognostic significance in 104 ovarian carcinomas. Survival analyses were performed according to the Kaplan-Meier method, as well as univariate and multivariate Cox proportional hazard regression analysis.
  
  
  RESULTS
  Positive expression of DBC1 and BRCA1 were seen in 63% (66/104) and 44% (46/104) of overall ovarian carcinomas, respectively. DBC1 expression was significantly associated with advanced clinicopathological factors such as high tumor stage, latent distant metastasis, platinum-resistance, elevated serum levels of CA125, high histologic grade, and BRCA1 expression. In the histological subtypes of ovarian carcinomas, DBC1 expression was more common in serous carcinoma (72%, 54/75) than mucinous carcinoma (15%, 3/20). BRCA1 expression was significantly associated with latent distant metastasis, platinum-resistance, and higher histologic grade. In addition, DBC1 expression was significantly associated with shorter overall survival (OS) and relapse-free survival (RFS) in 104 ovarian carcinomas (OS; P < 0.001, RFS; P < 0.001) and 63 high-grade serous carcinomas (OS; P = 0.008, RFS; P = 0.023) by univariate analysis. BRCA1 expression was significantly associated with OS and RFS in 104 ovarian carcinomas (OS; P = 0.005, RFS; P = 0.002) and 75 serous carcinomas (OS; P = 0.047, RFS; P = 0.038) by univariate analysis. Moreover, DBC1 expression was an independent prognostic indicator for OS in both 104 ovarian carcinomas (P = 0.021) and 63 high-grade serous carcinomas (P = 0.011) by multivariate analysis.
  
  
  CONCLUSIONS
  These results indicate that the expression of DBC1 and BRCA1 are closely related with in the progression of ovarian carcinomas and may have clinical utility in the prediction of prognosis of ovarian carcinomas. Especially, DBC1 expression could be employed as a significant prognostic indicator for ovarian carcinomas especially in high-grade serous carcinomas.
authors.forename: Dong
authors.initials: D
authors.lastname: Cho
authors.forename: Ho
authors.initials: H
authors.lastname: Park
authors.forename: See-Hyoung
authors.initials: SH
authors.lastname: Park
authors.forename: Kyoung
authors.initials: K
authors.lastname: Kim
authors.forename: Myoung
authors.initials: M
authors.lastname: Chung
authors.forename: Woo
authors.initials: W
authors.lastname: Moon
authors.forename: Myoung
authors.initials: M
authors.lastname: Kang
authors.forename: Kyu
authors.initials: K
authors.lastname: Jang
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000032:analysis / Q000096:biosynthesis*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019313:BRCA1 Protein; D014408:Biomarkers, Tumor / Q000032:analysis*; D002277:Carcinoma / Q000401:mortality / Q000473:pathology*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000401:mortality / Q000473:pathology*; D011379:Prognosis; D016016:Proportional Hazards Models; D046888:Tissue Array Analysis; D055815:Young Adult
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D019313:BRCA1 Protein; C492913:BRCA1 protein, human; D014408:Biomarkers, Tumor; C527450:CCAR2 protein, human
references.citation: Apoptosis. 2013 Aug;18(8):949-62
references.pmid: 23588592
references.citation: J Clin Oncol. 2008 Jan 1;26(1):20-5
references.pmid: 18165636
references.citation: Br J Cancer. 2002 Mar 18;86(6):879-85
references.pmid: 11953818
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: PLoS One. 2012;7(9):e45119
references.pmid: 23024800
references.citation: Exp Ther Med. 2011 Nov;2(6):1105-1109
references.pmid: 22977628
references.citation: Sci Signal. 2013 Apr 2;6(269):pl1
references.pmid: 23550210
references.citation: Transl Oncol. 2013 Jun 01;6(3):370-81
references.pmid: 23730418
references.citation: BMC Cancer. 2014;14:983
references.pmid: 25526776
references.citation: Am J Surg Pathol. 2008 Oct;32(10):1523-31
references.pmid: 18724249
references.citation: Cancer Sci. 2010 Jul;101(7):1738-44
references.pmid: 20412117
references.citation: Nature. 2008 Jan 31;451(7178):587-90
references.pmid: 18235502
references.citation: Front Oncol. 2014 Mar 03;4:34
references.pmid: 24624361
references.citation: Lancet. 2010 Jul 24;376(9737):235-44
references.pmid: 20609467
references.citation: Histol Histopathol. 2012 Jan;27(1):49-58
references.pmid: 22127596
references.citation: Br J Cancer. 2010 Mar 16;102(6):1061-7
references.pmid: 20160719
references.citation: Oncol Lett. 2012 Nov;4(5):873-877
references.pmid: 23162614
references.citation: Pathology. 2009;41(4):366-71
references.pmid: 19404850
references.citation: Gynecol Oncol. 2012 Jan;124(1):142-7
references.pmid: 22001143
references.citation: Hum Pathol. 2011 Feb;42(2):204-13
references.pmid: 21056897
references.citation: Mod Pathol. 1998 Feb;11(2):155-68
references.pmid: 9504686
references.citation: Clin Cancer Res. 2009 Jul 1;15(13):4453-9
references.pmid: 19509139
references.citation: Biosci Rep. 2013;33(4). pii: e00058. doi: 10.1042/BSR20130062
references.pmid: 23841676
references.citation: Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13647-52
references.pmid: 12370419
references.citation: Cancer. 2003 May 1;97(9):2187-95
references.pmid: 12712470
references.citation: Nature. 2008 Jan 31;451(7178):583-6
references.pmid: 18235501
references.citation: Proc Natl Acad Sci U S A. 2012 Jan 24;109(4):E187-96
references.pmid: 22190494
references.citation: Cancer Med. 2014 Dec;3(6):1553-61
references.pmid: 25146318
references.citation: Am J Surg Pathol. 2013 Jan;37(1):138-46
references.pmid: 23232854
references.citation: J Cell Biol. 2009 Apr 20;185(2):203-11
references.pmid: 19364925
references.citation: JAMA. 2012 Jan 25;307(4):382-90
references.pmid: 22274685
references.citation: Cancer Discov. 2012 May;2(5):401-4
references.pmid: 22588877
references.citation: Pathol Res Pract. 2014 Aug;210(8):533-40
references.pmid: 24947414
references.citation: Cancer Lett. 2013 Jun 10;333(2):180-6
references.pmid: 23352644
references.citation: J Biol Chem. 2009 Apr 17;284(16):10361-6
references.pmid: 19218236
references.citation: J Clin Invest. 2010 Feb;120(2):545-58
references.pmid: 20071779
references.citation: BMC Cancer. 2013;13:516
references.pmid: 24180625
references.citation: Int J Clin Oncol. 2014 Feb;19(1):106-12
references.pmid: 23299276
references.citation: PLoS One. 2013;8(9):e74738
references.pmid: 24019980
references.citation: J Biol Chem. 2009 Mar 13;284(11):6832-40
references.pmid: 19126541
references.citation: Pathology. 2013 Oct;45(6):574-80
references.pmid: 24018803
references.citation: Int J Cancer. 2015 Feb 15;136(4):797-809
references.pmid: 24962073
references.citation: J Proteomics Bioinform. 2013 Apr 18;Suppl 2:null
references.pmid: 24273392